Compass Therapeutics, Inc. (CMPX) Reports In-Line Q2 EPS

Compass Therapeutics, Inc. (NASDAQ: CMPX) reported Q2 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $850 million.

For earnings history and earnings-related data on Compass Therapeutics, Inc. (CMPX) click here.

You May Also Be Interested In

• Chevron signed an agreement with Iraq's Basra Oil Company to advance commercial negotiations for West Qurna 2
• Trump: I asked Darline Graham to run for U.S. senate in special Republican primary on Tuesday, August 11
• DWS Municipal Income Trust sets November 2026 liquidation timeline